Tumour DNA methylation markers associated with breast cancer survival: a replication study

Breast Cancer Research

Table 3 Associations of three tumour DNA methylation-based signatures with breast cancer-specific survival using MCCS data (N cases = 425, N breast cancer deaths = 66)

Methylation-based predictors of survival	Breast cancer-specific survival; N = 425; N deaths = 66
	Model 0^a		Model 1^a		Model 2^a		Model 3^a
	HR, 95%CI	P	HR, 95%CI	P	HR, 95%CI	P	HR, 95%CI	P
Du et al. [11]; 7 CpGs	1.12 (0.88,1.42)	0.37	1.22 (0.88,1.42)	0.35	0.97 (0.75,1.26)	0.83	1.00 (0.76,1.31)	0.97
Tao et al.[12]; 16 CpGs	1.41 (1.13,1.75)	0.002	1.40 (1.12,1.75)	0.003	1.22 (0.98,1.53)	0.08	1.22 (0.96,1.55)	0.10
Liu et al.[15]; 28 CpGs	1.62 (1.28,2.05)	5.5 × 10^–5	1.61 (1.27,2.05)	8.8 × 10^–5	1.40 (1.08,1.83)	0.01	1.48 (1.09,2.00)	0.01

^aModel 0: unadjusted; Model 1: adjusted for age and country of birth; Model 2: stratified for stage (I; II; III/IV) and IHC-based subtype (luminal A, luminal B, HER2-positive, triple-negative) + adjusted for age and country of birth; Model 3: Model 2 + additional adjustment for tumour purity

ISSN: 1465-542X